CLAIMS

1. A composition for delivery of dolasetron consisting of a condensation aerosol

a. formed by volatilizing a thin layer of dolasetron on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of dolasetron and condensing the heated vapor of dolasetron to form condensation aerosol particles,

b. wherein said condensation aerosol particles are characterized by less than 5% dolasetron degradation products, and

c. the condensation aerosol has an MMAD of less than 3 microns.

2. The composition according to Claim 1, wherein the aerosol particles are formed at a rate of at least 10^9 particles per second.

3. The composition according to Claim 2, wherein the aerosol particles are formed at a rate of at least 10^{10} particles per second.

4. A composition for delivery of granisetron consisting of a condensation aerosol

a. formed by volatilizing a thin layer of granisetron on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of granisetron and condensing the heated vapor of granisetron to form condensation aerosol particles,

b. wherein said condensation aerosol particles are characterized by less than 5% granisetron degradation products, and

c. the condensation aerosol has an MMAD of less than 3 microns.

5. The composition according to Claim 4, wherein the aerosol particles are formed at a rate of at least 10^9 particles per second.

6. The composition according to Claim 5, wherein the aerosol particles are formed at a rate of at least 10^{10} particles per second.

7. A composition for delivery of metoclopramide consisting of a condensation aerosol

a. formed by volatilizing a thin layer of metoclopramide on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of metoclopramide and condensing the heated vapor of metoclopramide to form condensation aerosol particles,

b. wherein said condensation aerosol particles are characterized by less than 5% metoclopramide degradation products, and

c. the condensation aerosol has an MMAD of less than 3 microns.

8. The composition according to Claim 7, wherein the aerosol particles are formed at a rate of at least 10^{9} particles per second.

9. The composition according to Claim 8, wherein the aerosol particles are formed at a rate of at least 10^{10} particles per second.

10. A method of producing dolasetron in an aerosol form comprising:

a. heating a thin layer of dolasetron on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the dolasetron to form a heated vapor of the dolasetron, and

b. during said heating, passing air through the heated vapor to produce aerosol particles of the dolasetron comprising less than 5% dolasetron degradation products, and an aerosol having an MMAD of less than 3 microns.

11. The method according to Claim 10, wherein the aerosol particles are formed at a rate of greater than 10^{9} particles per second.

12. The method according to Claim 11, wherein the aerosol particles are

formed at a rate of greater than 10^{10} particles per second

13. A method of producing granisetron in an aerosol form comprising:

a. heating a thin layer of granisetron on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the granisetron to form a heated vapor of the granisetron, and

b. during said heating, passing air through the heated vapor to produce aerosol particles of the granisetron comprising less than 5% granisetron degradation products, and an aerosol having an MMAD of less than 3 microns.

14. The method according to Claim 13, wherein the aerosol particles are formed at a rate of greater than 10^{9} particles per second.

15. The method according to Claim 14, wherein the aerosol particles are formed at a rate of greater than 10^{10} particles per second.

16. A method of producing metoclopramide in an aerosol form comprising:

a. heating a thin layer of metoclopramide on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the metoclopramide to form a heated vapor of the metoclopramide, and

b. during said heating, passing air through the heated vapor to produce aerosol particles of the metoclopramide comprising less than 5% metoclopramide degradation products, and an aerosol having an MMAD of less than 3 microns.

17. The method according to Claim 16, wherein the aerosol particles are formed at a rate of greater than 10^{9} particles per second.

18. The method according to Claim 17, wherein the aerosol particles are formed at a rate of greater than 10^{10} particles per second.